RYSE head tells Medtech Insight about his firm’s shift to investing in virtual primary care and telemedicine.
Securing funding for early-stage companies is a challenge at the best of times but with COVID19 the challenge may be even greater. For London-based asset management firm RYSE, the pandemic caused a rethink of its six-month investment program for early-stage digital health and medtech start-ups.
The firm's second funding call, launched in 2019, invited start-ups to apply for £250k-£5m in funding with the opportunity to work alongside RYSE and its partners, DigitalHealth.London and MedCity.
"Although it delayed the process, it allowed us to sharpen our knife trying to understand exactly which companies we want to invest in as we had to include COVID-19 as a new input when it came to the selection of the investee companies," RYSE managing partner Claudio D'Angelo told MedTech Insight.
You can read the full article on the MedTech Insight website here.